熱門資訊> 正文
Surmodics合并交易引发FTC第二次请求
2024-08-13 19:00
- Medical device maker Surmodics (NASDAQ:SRDX) announced Tuesday that the Federal Trade Commission (FTC) has requested more information on its pending merger agreement with the affiliates of private equity firm GTCR.
- Surmodics (SRDX) and BCE Parent, LLC, an affiliate of a GTCR-backed entity, received the FTC Second Request on Aug. 12, the company said in a regulatory filing.
- It is meant to extend the waiting period imposed by the antitrust regulation, the Hart-Scott-Rodino Antitrust Improvements Act of 1976, until 30 days after the merging entities comply with the request.
- Surmodics (SRDX) added that the deal is expected to conclude before Feb. 28, 2025, the outside date mentioned in the merger agreement.
- When the company and acquirer signed the all-cash buyout deal in March, they expected to conclude the transaction in H2, 2024.
More on Surmodics
- Surmodics beats top-line and bottom-line estimates; suspends annual guidance
- Surmodics jumps 18% on acquisition by GTCR
- Seeking Alpha’s Quant Rating on Surmodics
- Historical earnings data for Surmodics
- Financial information for Surmodics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
